Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene
نویسندگان
چکیده
منابع مشابه
Clinicopathologic Features of Patients with Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Gene: A Meta-Analysis
BACKGROUND The frequencies of EML4-ALK fusion gene in non-small cell lung cancer (NSCLC) with different clinicopathologic features described by previous studies are inconsistent. The key demographic and pathologic features associated with EML4-ALK fusion gene have not been definitively established. This meta-analysis was conducted to compare the frequency of the EML4-ALK fusion gene in patients...
متن کاملPre-Treatment Serum CEA and EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma
Lung cancer is the most common cause of cancerrelated deaths, where it is associated with a 5-year worldwide survival rate of less than 15% (Jemal et al., 2011). Among new diagnoses of pulmonary carcinoma, Non-small-cell lung cancer (NSCLC) accounts for approximately 80% (Ozgul et al., 2013). Despite great efforts to improve the survival of patients with NSCLC, the outcomes are still considered...
متن کاملSEC31A-ALK Fusion Gene in Lung Adenocarcinoma
Anaplastic lymphoma kinase (ALK) fusion is a common mechanism underlying pathogenesis of non-small cell lung carcinoma (NSCLC) where these rearrangements represent important diagnostic and therapeutic targets. In this study, we found a new ALK fusion gene, SEC31A-ALK, in lung carcinoma from a 53-year-old Korean man. The conjoined region in the fusion transcript was generated by the fusion of SE...
متن کاملClinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis
BACKGROUND A novel fusion gene of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has been recently identified in non-small-cell lung cancers (NSCLCs). Patients with the EML4-ALK fusion gene demonstrate unique clinicopathological and physiological characteristics. Here we present a meta-analysis of large-scale studies to evaluate the clinicopathologi...
متن کاملResponse to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis
BACKGROUND Lung cancer with ovarian metastasis or adnexal metastasis harboring anaplastic lymphoma kinase (ALK) gene translocation is rare. Crizotinib, a novel ALK tyrosine kinase inhibitor, has already shown an impressive single-agent activity in ALK positive lung cancer. METHODS To summarize the case of clinical data and treatment of a 33-year-old woman with pelvic adnexal metastasis NSCLC....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thoracic Cancer
سال: 2018
ISSN: 1759-7706
DOI: 10.1111/1759-7714.12616